BTS statement on malignant mesothelioma in the UK, 2007. - Wikidata - wikimedia - TriplyDB

BTS statement on malignant mesothelioma in the UK, 2007.

BTS statement on malignant mesothelioma in the UK, 2007.

http://www.wikidata.org/entity/Q30478994

about

Malignant mesothelioma Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions Factors that impact susceptibility to fiber-induced health effects Guidelines for the diagnosis and treatment of malignant pleural mesothelioma Modern management of malignant pleural mesothelioma A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.Malignant pleural mesothelioma: an epidemiological perspective The role of interleukin-6 in malignant mesothelioma Pleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions?Pleural mesothelioma surveillance: validity of cases from a tumour registry Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.What is the survival after surgery for localized malignant pleural mesothelioma?Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos.Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Grou What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK.Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).Asbestos-related pleuropulmonary diseases: benign and malignant.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Pleural procedures in the management of malignant effusions.Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma.Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma.Working with asbestos and the possible health risks.p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.Pleural effusion: what lies underneath?Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.Malignant mesothelioma: Canadian perspective and research directions.Asbestos Ban in Italy: A Major Milestone, Not the Final Cut.Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.Malignant mesothelioma as a difficult interdisciplinary problem.Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma.Should cytology be an acceptable means of diagnosing malignant mesothelioma?New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

P2860

Q21202901-9125C70B-A0B8-470D-985B-D04CBADBC9A5 Q28238665-9A616307-DBC9-4C32-AA2A-53A667A4C504 Q28389535-9DD858D7-93A6-4CC3-B7B0-AAE6EBE01EBB Q28394028-BFDBAE70-EC68-4412-A5A8-1652D40D6ACB Q29248127-EE9491F2-64F3-4C87-B6D4-00F4C9F7C7F3 Q30588623-77690539-257E-4236-813E-F591D1173663 Q30614413-2AFCEE6C-8823-42C4-BA4B-ABBC7F44F8C1 Q30790098-0F6210A0-E9E2-4D36-A820-AF8165316C1F Q33815929-DB16BD8A-A59B-45EA-A8FF-302C9AF00EA9 Q34130373-FCC79FE8-E547-4373-A73D-55F74C7A172C Q34366730-4B93AAC5-E2A1-4D65-8171-7299CF2F56E8 Q35200628-858CA8BA-551A-4B50-930D-8B3DAC5C9ECD Q35739564-6EEF6C06-9665-41A7-9403-89CC0B665A7E Q36027122-1EFBB6E7-2E9D-493A-BA95-4E96DDB80B1E Q36526737-373A8FAB-D7A2-47CE-A5DA-2123700AB8ED Q36685838-0BCABA41-177E-4CEF-BEC4-992E61BCB0D0 Q36766690-55533CC2-D9F6-46C0-9D60-3920979446E1 Q36820998-0589358A-034C-4467-8853-493B5CAB2FC9 Q36990070-134E754F-5CBD-4506-AF7E-C7E772F84B3D Q37252039-3D296F2F-192F-466F-A02D-1778F5CB00F4 Q37277434-7EDA9F5B-871C-4F8C-B822-F50C94B3D677 Q38018217-E680F320-4EF2-4141-BA7B-BDD194EF6CDA Q38118298-AAA91106-C856-4F8A-B4E7-7DB5A41847BF Q39135624-B1E64979-15F9-43CC-A524-30A937C9C11D Q40166240-6EAD8FD4-A36A-4771-8704-0CA1DBCA27A1 Q40336711-853D14E3-3A54-4462-B630-7663AF6DD284 Q41371658-8F6BE699-8386-48D8-8BD8-8F8C87F375D8 Q41624155-7B533E5C-98BB-469B-AED9-DD812D8F04C7 Q41849387-F8E25DD5-E98D-4671-8075-65056C68B5FF Q42582696-CCB2449A-5BBB-4ABC-B348-87E54628EE0E Q45327540-2E8C6FEA-1A9C-4A6F-A029-8F27DEEC7623 Q47096401-886CB92E-9E00-4EB6-987F-E630EC0D1DDA Q47098675-B632D10A-70F6-4DE0-9C17-B4BBBF4C314B Q47119595-75DF37DF-E3CB-4515-B539-BD8FF5CCF9DD Q48060347-FA3CE46D-A984-4C2C-AB10-1414D69CD367 Q48514792-758C324C-DB98-4D1C-97E1-B06BCDEFACF6 Q49804857-4FDEA93B-E611-4A29-BEB8-3E6A5DE4C0F9 Q50281750-DA484843-BC5A-46E4-9B95-FDCDE371B120 Q51767012-5B37AE7C-F289-4C90-A468-A5DAAB2A74CB Q52581757-B6D5509A-2090-4BAD-82F7-E449D110464C

P2860

BTS statement on malignant mesothelioma in the UK, 2007.

http://www.wikidata.org/entity/Q30478994

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

BTS statement on malignant mesothelioma in the UK, 2007.

@ast

BTS statement on malignant mesothelioma in the UK, 2007.

@en

type

label

BTS statement on malignant mesothelioma in the UK, 2007.

@ast

BTS statement on malignant mesothelioma in the UK, 2007.

@en

prefLabel

BTS statement on malignant mesothelioma in the UK, 2007.

@ast

BTS statement on malignant mesothelioma in the UK, 2007.

@en

P1433

Q30478994-5FD95F94-A358-4FF6-B7A2-3F0F80810EEE

P1476

Q30478994-9B830D81-F5D2-428B-93A1-95C25F108F9C

P2093

Q30478994-4514C1C4-F265-4A16-9215-9820AD2F37FE

P2860

Q30478994-000B2A6B-E05D-4B89-AF6C-7635621F52F3

Q30478994-012B8B6D-F27D-4BD7-9A55-F970174B1170

Q30478994-022E7F8B-C9C6-4C3E-A237-F0F2B6DFD819

Q30478994-042E7D8B-A359-4A6B-B9FE-169E64117AE2

Q30478994-0510BC73-11B3-42C0-9A06-9E66C8257883

Q30478994-078718DB-BD93-48D6-B138-E44B597E37C1

Q30478994-17CED112-0A6D-4A62-807A-689EE95FF9C3

Q30478994-19951EBC-8889-4AE1-970E-114B442C18BA

Q30478994-1B5A6317-E732-4EB6-8BD6-F57128D79643

Q30478994-1C34CC95-7C31-43A5-AF23-A3D94216420D

P304

Q30478994-BA3CB795-196D-4701-8B51-BAE158CE9F0A

P31

Q30478994-721BFD17-7987-4BA1-A79F-702D6C8A4591

P356

Q30478994-E66BCBC0-2B84-4D2A-90D6-B4715C3A5A17

P407

Q30478994-8B7B5D9E-8C2B-4A01-8804-E0F2DB4946A2

P478

Q30478994-882C67F6-8388-4573-9163-A1E3322239D7

P577

Q30478994-AECEC742-E384-4B46-AB0A-F79D15247726

P5875

Q30478994-E3D75A5A-2A69-44AB-9ED7-42A3578EC6AE

P698

Q30478994-C85341D3-CD9A-4F22-A1CB-3F5A1CBDE046

P932

Q30478994-936EE08F-E2D4-4531-AE23-DB6300D0880D

P356

THX.2007.087619

P1433

P1476

BTS statement on malignant mesothelioma in the UK, 2007.

@en

P2093

British Thoracic Society Standards of Care Committee

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial

Statement on malignant mesothelioma in the United Kingdom

Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.

Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.

Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter.

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.

Pemetrexed in malignant pleural mesothelioma.

P304

ii1-ii19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2007.087619

http://www.w3.org/2001/XMLSchema#string

P407

P478

62 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47623646

http://www.w3.org/2001/XMLSchema#string

P698

17965072

http://www.w3.org/2001/XMLSchema#string

P932

2094726

http://www.w3.org/2001/XMLSchema#string